- Report
- October 2024
- 195 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2024
- 100 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2025
- 354 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 187 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- May 2024
- 129 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- February 2024
- 126 Pages
Global
From €2842EUR$2,990USD£2,388GBP
- Report
- January 2022
- 108 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- April 2023
- 110 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- December 2022
- 118 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- March 2021
- 130 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- July 2023
- 90 Pages
Global
From €3500EUR$3,944USD£3,043GBP

The Intravenous Iron market is a segment of the Hematological Drugs market, which includes drugs used to treat anemia and other blood disorders. Intravenous Iron is a type of drug used to treat iron deficiency anemia, a condition in which the body does not have enough iron to produce healthy red blood cells. Intravenous Iron is administered directly into the bloodstream, allowing for a more rapid increase in iron levels than oral iron supplements.
Intravenous Iron is used in a variety of settings, including hospitals, clinics, and home care. It is often prescribed to patients who are unable to take oral iron supplements due to gastrointestinal issues or who require a more rapid increase in iron levels.
The Intravenous Iron market is highly competitive, with a number of companies offering products in this space. Some of the major players in the market include Vifor Pharma, Fresenius Kabi, American Regent, and B. Braun. Show Less Read more